New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 200ug; vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg;   - powder for inhalation - 200mcg/25mcg - active: fluticasone furoate 200ug vilanterol trifenatate 40ug equivalent to vilanterol 25 mcg   excipient: lactose monohydrate magnesium stearate - indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg;   - powder for inhalation - 62.5 mcg - active: umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg   excipient: lactose monohydrate magnesium stearate - incruse ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - betamethasone valerate 0.122%{relative} equivalent to 0.1% betamethasone - lotion - 0.1 % - active: betamethasone valerate 0.122%{relative} equivalent to 0.1% betamethasone excipient: cetomacrogol 1000 cetostearyl alcohol citric acid monohydrate glycerol isopropyl alcohol liquid paraffin methyl hydroxybenzoate purified water sodium citrate dihydrate xanthan gum - betnovate lotion is a potent topical corticosteroid indicated foradults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. these include the following: ·atopic dermatitis (including infantileatopic dermatitis) ·nummular dermatitis (discoid eczema) ·prurigo nodularis ·psoriasis (excluding widespread plaque psoriasis) ·lichen simplex chronicus (neurodermatitis) and lichen planus ·seborrhoeic dermatitis ·irritant or allergic contact dermatitis ·discoid lupus erythematosus ·insect bite reactions ·miliaria (prickly heat); and ·adjunct to systemic steroid therapy in generalised erythroderma.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - betamethasone valerate 0.1%{relative}; clioquinol 3%{relative};   - topical cream - 0.1%/3% - active: betamethasone valerate 0.1%{relative} clioquinol 3%{relative}   - betnovate-c preparations are indicated for the treatment of the following conditions where secondary bacterial and/or fungal infection is present, suspected or likely to occur:- eczema including atopic, and discoid eczemas. prurigo nodularis. psoriasis (excluding widespread plaque psoriasis). neurodermatoses including lichen simplex, lichen planus. seborrhoeic dermatitis. contact sensitivity reactions. insect bite reactions. prickly heat. anal and genital intertrigo. otitis externa.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - maraviroc 150mg;   - film coated tablet - 150 mg - active: maraviroc 150mg   excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose opadry blue 85g20583 sodium starch glycolate - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - maraviroc 300mg;   - film coated tablet - 300 mg - active: maraviroc 300mg   excipient: calcium hydrogen phosphate magnesium stearate microcrystalline cellulose opadry blue 85g20583 sodium starch glycolate - celsentri, in combination with other antiretroviral medicinal products, is indicated for adult patients infected with only ccr5-tropic hiv-1. the use of other active agents with celsentri is associated with a greater likelihood of treatment response.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - sumatriptan succinate 16.8 mg/ml;   - solution for injection - 6 mg/0.5ml - active: sumatriptan succinate 16.8 mg/ml   - imigran injection is indicated for the acute relief of migraine attacks with or without aura, and for the acute treatment of cluster headache.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - sumatriptan succinate 140mg equivalent to 100 mg sumatriptan base;   - tablet - 100 mg - active: sumatriptan succinate 140mg equivalent to 100 mg sumatriptan base   excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opaspray white m-1-7120 purified water - imigran tablets are indicated for the acute relief of migraine attacks with or without aura in adults aged 18 to 65 years.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - sumatriptan succinate 70mg equivalent to 50 mg sumatriptan base;   - tablet - 50 mg - active: sumatriptan succinate 70mg equivalent to 50 mg sumatriptan base   excipient: croscarmellose sodium lactose lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink ys-1-1441-g purified water - imigran tablets are indicated for the acute relief of migraine attacks with or without aura in adults aged 18 to 65 years.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - warfarin sodium 1mg - tablet - 1 mg - active: warfarin sodium 1mg excipient: indigo carmine iron oxide red iron oxide yellow lactose monohydrate magnesium stearate maize starch pregelatinised maize starch sodium starch glycolate - coronary occlusion; deep vein thrombosis; pulmonary embolism; peripheral vascular thromboembolic states.